Sputnik V induced sera to the internationally relevant variants with the neutralizing activity to the ancestral B.1.1.1 variant.
The Gamaleya Center and RDIF are also studying new opportunities to develop vaccine cocktails jointly with other leading COVID vaccine producers using the first component of Sputnik V.
Sputnik V has been registered in 67 countries globally with a total population of over 3.5 billion people. "RDIF will continue supporting further studies of the efficacy of Sputnik V against new strains while also analyzing opportunities to partner with other leading vaccine producers for developing vaccine cocktails using the first shot of Sputnik V," said Kirill Dmitriev, CEO of the RDIF.